175 398

Cited 8 times in

Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy

 Won Hyuk Choi  ;  Sungsoo Kim  ;  Woo Jin Hyung  ;  Jeong Sik Yu  ;  Chan Il Park  ;  Seung Ho Choi  ;  Sung Hoon Noh 
 YONSEI MEDICAL JOURNAL, Vol.50(3) : 437-440, 2009 
Journal Title
Issue Date
Benzamides ; Gastrointestinal Stromal Tumors/drug therapy* ; Gastrointestinal Stromal Tumors/surgery* ; Humans ; Imatinib Mesylate ; Male ; Middle Aged ; Piperazines/therapeutic use* ; Protein Kinase Inhibitors/therapeutic use* ; Pyrimidines/therapeutic use* ; Treatment Outcome
Gastrointestinal stromal tumors ; Imatinib ; cytoreductive surgery ; recurrence
In the treatment of recurrent or metastatic gastrointestinal stromal tumors (GIST), good prognoses may not be expected by surgery alone. Recently, imatinib has been applied for the treatment of GISTs, resulting in improved patient survival. However, long-term success is limited due to the development of resistance. Herein, we report two cases of long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. A 49 year-old man was diagnosed to a duodenal GIST with single hepatic metastasis, and an antrectomy including the duodenal lesion with intraoperative radiofrequency ablation were performed in April, 2002. After four months, a new metastatic hepatic lesion was identified. Percutaneous radiofrequency ablation was done, and imatinib therapy was started. A 56 year-old man underwent laparoscopic segmental resection of the distal ileum and partial excision of parietal peritoneum in March, 2001 to treat a malignant GIST of the distal ileum that was attached to parietal peritoneum. After six months, recurrence of GIST with peritoneal seeding and hepatic metastasis was found, and he underwent cytoreductive surgery including right hemicolectomy and wedge resection of liver. After surgery, there was no residual tumor grossly and imatinib therapy was started. In both cases, they were doing well with no evidence of recurrence for 5 years with imatinib therapy. Therefore, in patients with a recurrent GIST, improved survival can be expected with imatinib therapy after cytoreductive surgery
Files in This Item:
T200903319.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sung Soo(김성수)
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Park, Chan Il(박찬일)
Yu, Jeong Sik(유정식) ORCID logo https://orcid.org/0000-0002-8171-5838
Choi, Seung Ho(최승호) ORCID logo https://orcid.org/0000-0002-9872-3594
Choi, Won Hyuk(최원혁)
Hyung, Woo Jin(형우진) ORCID logo https://orcid.org/0000-0002-8593-9214
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.